Cellular and Immune Therapy for Treating HIV-1 Infection.

IF 1.9 4区医学 Q4 IMMUNOLOGY AIDS reviews Pub Date : 2021-02-24 DOI:10.24875/AIDSRev.20000110

Wei Li, Qiqiang Zhou, Lingbo Xia, Ruixiang Zou, Wei Zou

引用次数: 0

Abstract

HIV-1 infection has caused a number of deaths worldwide and remains a global health concern. Combined antiretroviral therapy (cART) inhibits viral replication, prevents CD4+ T cell loss, and thus slows HIV disease progression. However, cART does not eradicate HIV-1. Infected individuals must remain on treatment for their entire lives and treatment interruption will result in viral rebound.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

细胞和免疫疗法治疗HIV-1感染。

艾滋病毒-1感染在全世界造成若干人死亡，仍然是一个全球健康问题。联合抗逆转录病毒疗法(cART)抑制病毒复制，防止CD4+ T细胞损失，从而减缓艾滋病毒疾病进展。然而，cART并不能根除HIV-1。感染者必须终生接受治疗，治疗中断将导致病毒反弹。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

AIDS reviews 医学-传染病学

CiteScore

3.40

自引率

4.50%

发文量

审稿时长

>12 weeks

期刊介绍： AIDS Reviews publishes papers reporting original scientific, clinical, epidemiologic and social research which contribute to the overall knowledge of the field of the acquired immunodeficiency syndrome and human retrovirology. Currently, the Journal publishes review articles (usually by invitation, but spontaneous submitted articles will also be considered). Manuscripts submitted to AIDS Reviews will be accepted on the understanding that the authors have not submitted the paper to another journal or published the material elsewhere.

期刊最新文献

Sexually transmitted infections keep rising up. The burden of HIV-1 and HIV-2 epidemics in Ivory Coast. Monkeypox 2024 outbreak. Playing catching up: Proceedings of the 1^st Spanish conference on genomic medicine. Strengthen the doctor-patient relationship and avoid administrative stifling.